Somatuline Autogel: Acromegaly Self/Partner Injection Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00149188|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : June 19, 2012
|Condition or disease||Intervention/treatment||Phase|
|Acromegaly||Drug: Lanreotide (Autogel formulation)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel.|
|Study Start Date :||February 2004|
- To assess the ability of patients or their partners to perform unsupervised Somatuline Autogel injections.
- To assess whether administration of unsupervised injections of Somatuline Autogel has any effect on GH and IGF-1 control or serum lanreotide levels.
- To assess patient/partner and healthcare professional experience with unsupervised injections.
- To assess the safety of patients or their partners performance of unsupervised Somatuline Autogel injections.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00149188
|Michael White Centre Diabetes & Endocrinology, Hull Royal Infirmary|
|Hull, East Yorkshire, United Kingdom, HU3 2JZ|
|Department of Endocrinology, The Royal Free Hospital|
|Hampstead, London, United Kingdom, NW3 2QG|
|Dept of Endocrinology, Aberdeen Royal Infirmary|
|Aberdeen, United Kingdom, AB25 2ZN|
|Department of Medicine, Queen Elizabeth Hospital|
|Birmingham, United Kingdom, B15 2TH|
|Department of Endocrinology, Coventry & Warwickshire Hospital|
|Coventry, United Kingdom, CV1 4FH|
|Department of Endocrinology, Leicester Royal Infirmary|
|Leicester, United Kingdom, LE1 5WW|
|Department of Endocrinology, Manchester Royal Infirmary|
|Manchester, United Kingdom, M13 9WL|
|The Oxford Centre for Diabetes, Endocrinology and Metabolism, The Churcill Hospital|
|Oxford, United Kingdom, OX3 7LJ|
|Department of Endocrinology, Royal Hallamshire Hospital|
|Sheffield, United Kingdom, S10 2JF|
|Department of Endocrinology, Sunderland Royal Hospital|
|Sunderland, United Kingdom, SR4 7TP|
|Study Director:||UK Medical Director, MD||Ipsen|